Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-07-30 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于股东股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company (贝达药业股份有限公司) regarding the release of pledged shares by a shareholder (浙江济和创业投资有限公司). It details the number of shares released from pledge, the dates, and the pledgee bank. It also provides cumulative pledge information for the shareholder and related parties. The document is short (1471 characters) and focuses solely on share pledge status changes. There is no financial report, earnings data, or management discussion. This fits the category of announcements related to shareholding changes, specifically about share pledges and releases. According to the filing definitions, this corresponds to Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related shareholding status changes such as pledges.
2020-07-30 Chinese
关于股东股份解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company about the release of pledged shares by a shareholder. It details the number of shares released from pledge, the shareholder involved, and the status of pledged shares. There is no financial statement, earnings data, or management discussion. The content focuses on changes in share pledges, which is a capital structure update but specifically about share pledging and release. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges and releases.
2020-07-24 Chinese
关于收到《关于贝达药业股份有限公司申请向特定对象发行股票的审核中心意见告知函》的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the receipt of an opinion letter from the Shenzhen Stock Exchange's listing review center about the company's application for a private placement of shares. It mentions the review of the application for issuing shares to specific investors and the subsequent registration process with the China Securities Regulatory Commission. The document is short (523 characters) and serves as an announcement of a regulatory review and next steps rather than a detailed financial report or data. It does not contain financial statements or detailed analysis but is an update on capital raising activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2020-07-23 Chinese
拟股权转让涉及的浙江贝达医药科技有限公司股东全部权益价值评估项目资产评估报告
Regulatory Filings
2020-07-21 Chinese
关于对深圳证券交易所问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.) responding to an inquiry letter from the Shenzhen Stock Exchange regarding the sale of a subsidiary's equity to a related party. It includes extensive explanations about the transaction, the evaluation method used for the subsidiary's valuation, financial data of the subsidiary, and the rationale and fairness of the transaction. The document is not a full financial report but a regulatory disclosure addressing a specific inquiry about a related-party transaction and its impact on the company. It contains detailed financial and valuation information but is primarily a regulatory response and announcement rather than a comprehensive financial report like an Annual Report or Interim Report. It does not fit into categories like Earnings Release or Capital Update but aligns best with Regulatory Filings (RNS) as it is a compliance disclosure responding to a regulatory inquiry and explaining the transaction details.
2020-07-21 Chinese
关于股东股份解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company about the release of pledged shares by a shareholder. It details the number of shares released from pledge, the shareholder involved, and the status of pledged shares. There is no financial statement, earnings data, or management discussion. The document is short (1670 characters) and focuses on share pledge status changes, which is a capital structure related update. This fits best under the category of Capital/Financing Update (CAP).
2020-07-14 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.